Table 4.

Impact of Randomized Rosuvastatin Therapy Versus Placebo on HDL-Related Biomarkers Levels

HDL Phenotype	Placebo	Rosuvastatin	P Value vs. Placebo
HDL Cholesterol
N	481	369
Mean at baseline, mg/dl	51.0	51.6
Mean at 12mo, mg/dl	51.8	54.8
Percent Change (95%CI)	2.6 (1.2 – 2.4)	7.7 (5.8 – 9.5)	<0.0001
P Value vs. Baseline	0.0003	<0.0001
Apolipoprotein A-I
N	476	364
Mean at baseline, mg/dl	161.5	162.6
Mean at 12mo, mg/dl	163.4	168.2
Percent Change (95%CI)	1.9 (0.7 – 3.1)	4.3 (2.7 – 6.0)	0.02
P Value vs. Baseline	0.002	<0.0001
HDL Particle Number
N	428	312
Mean at baseline, μmol/l	31.5	31.4
Mean at 12mo, μmol/l	31.4	33.2
Percent Change (95%CI)	−1.6 (−3.1 – 0.1)	5.2 (3.1–7.3)	<.0001
P Value vs. Baseline	0.04	<0.0001
Cholesterol Efflux Capacity
N	369	248
Mean at baseline, %	14.9	15.2
Mean at 12mo, %	14.1	13.8
Percent Change (95%CI)	−3.3 (−7.9 – 1.2)	−1.5 (−13.3 – 10.2)	0.78
P Value vs. Baseline	0.15	0.80

Mean percent changes from baseline to twelve-months of therapy calculated. P values versus baseline and placebo determined via one-sample and two-sample t tests respectively.